moyamoya disease
Conditions
Interventions
Experiment group:Intervention:Traditional Chinese medicine combined with conventional treatment.
Control group:All enrolled patients underwent surgical treatment with combined cerebral blood flow reconstructive surgery. Cerebral blood flow reconstruction mainly includes three types: direct blood
Superficial arterion-ACA or superficial temporal arterion-PCA anastomosis can be used as a supplement or substitute when the ischemic area is located in the ACA or PCA feeding area: occipital artery o
Occipital arterio-PCA anastomosis is mainly used to improve the perfusion of the PCA blood flow distribution area, and is rarely used. (2) The basic principle of indirect blood flow reconstruction is
Sponsors
Nanyang central hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Hospitalized patients with definite diagnosis of moyamoya disease; 2. Previous cerebral ischemia symptoms, including dizziness, headache, reversible neurological deficits, transient ischemic attacks, limb movement disorders, cerebral infarction, seizures, etc.; 3. During hospitalization, the patient underwent combined cerebral revascularization. 4. 18 years old = age =75 years old; 5. The patients voluntarily participated in the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. The patient had a history of subarachnoid hemorrhage, ventricular hemorrhage, and parenchymal hemorrhage. 2. The patient had severe cognitive dysfunction due to cerebrovascular events and could not cooperate with the examination; 3. Cerebrovascular examination indicated that the patient had other cerebrovascular diseases, such as intracranial aneurysm and intracranial arteriovenous malformation. 4. Moyamoya disease combined with hyperthyroidism, systemic lupus erythematosus and other immune diseases; 5. The patient has hemophilia or thrombocytopenia or other clotting disorders; 6. Because atherosclerosis risk factors (such as hypertension, diabetes, hyperlipidemia, heavy smoking, alcoholism, etc.) may affect the formation of collateral circulation, patients with more than two risk factors were excluded; 7. Complicated with malignant tumors, severe liver and kidney failure or other systemic diseases; 8. Use of the investigational drug within 3 months prior to screening or trial, or participation with another clinical investigator within 30 days prior to treatment; 9. Pregnant or lactating women; 10. People with mental illness, severe depression, alcohol dependence, or a history of substance abuse; 11. People who are known to be allergic to Buhuang Siwu decoction ingredients or allergic to contrast agents; 12. The investigator judged that it was not possible to complete or not appropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Formation of collateral circulation; | — |
Secondary
| Measure | Time frame |
|---|---|
| 90-day mRS Score;MO CA assessment Scale; TCM syndrome scoring ;Vascular bridging rate;Number of endothelial progenitor cells;basic fibroblast growth factor ;vascular endothelial growth factor;Intestinal microorganisms and metabolites;Eukaryotic reference transcriptome sequencing;Non-targeted metabolome detection;Whole exon capture and sequencing;Collateral circulation compensatory state;Cerebral perfusion state; | — |
Countries
China
Contacts
Public ContactBAI Fanghui
Nanyang central hospital
Outcome results
None listed